Omega-3-acid ethyl esters
- Generic Name
- Omega-3-acid ethyl esters
- Brand Names
- Lovaza, Omtryg
- Drug Type
- Small Molecule
- CAS Number
- 308081-97-2
- Unique Ingredient Identifier
- D87YGH4Z0Q
- Background
Omega-3-acid ethyl esters are prescription drugs that contain eicosapentaenoic acid-ethyl ester (EPA) and docosahexaenoic acid-ethyl ester (DHA) that are used in combination with changes in diet to lower triglyceride levels in adults with severe (≥ 500 mg/dL) hypertriglyceridemia. Omega-3-acid ethyl esters are currently marketed in the US, EU, and many other regions under the brand name Lovaza.
- Indication
Omega-3-Acid Ethyl Esters capsules, USP are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia (HTG).
- Associated Conditions
- Severe Hypertriglyceridemia (sHTG)
Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals
- Conditions
- Hypertriglyceridemia
- Interventions
- First Posted Date
- 2011-09-09
- Last Posted Date
- 2015-04-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 52
- Registration Number
- NCT01431690
Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia
- First Posted Date
- 2010-10-27
- Last Posted Date
- 2011-11-24
- Lead Sponsor
- Trygg Pharma, Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT01229566
- Locations
- 🇺🇸
Illinois Recruiting, Chicago, Illinois, United States
Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation
- Conditions
- Severe Hypertriglyceridemia
- Interventions
- Drug: Epanova (4 g) and Lovaza (4 g)
- First Posted Date
- 2010-09-24
- Last Posted Date
- 2015-07-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 54
- Registration Number
- NCT01208961
- Locations
- 🇺🇸
Radiant Research, Chicago, Illinois, United States
Investigational Study of Oral Fish Oil in Treating Parenteral Nutrition Associated Liver Disease
- Conditions
- Liver DiseaseShort Bowel Syndrome
- Interventions
- Dietary Supplement: Corn oil
- First Posted Date
- 2010-08-30
- Last Posted Date
- 2017-06-22
- Lead Sponsor
- Boston Children's Hospital
- Registration Number
- NCT01191177
- Locations
- 🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States
Effects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in Hypertriglyceridemia
- Conditions
- Hypertriglyceridemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-08-12
- Last Posted Date
- 2016-02-08
- Lead Sponsor
- University of Utah
- Registration Number
- NCT01180764
- Locations
- 🇺🇸
University of Utah, Salt Lake City, Utah, United States
Parenteral Nutrition Associated Liver Disease: Early Markers and Therapy Wih Enteral Omega-3 Supplementation
- Conditions
- Parenteral Nutrition Associated Liver Disease
- Interventions
- First Posted Date
- 2010-07-07
- Last Posted Date
- 2011-06-17
- Lead Sponsor
- University of Tennessee
- Target Recruit Count
- 100
- Registration Number
- NCT01157780
- Locations
- 🇺🇸
Le Bonheur Children's Medical Center, Memphis, Tennessee, United States
The Effects of Lovaza® in Acute Myocardial Infarction
- Conditions
- Myocardial Infarction
- Interventions
- Drug: The placebo contained 1 gram of corn oil in each capsule.
- First Posted Date
- 2010-07-01
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 4
- Registration Number
- NCT01155336
- Locations
- 🇺🇸
University or Rochester, Rochester, New York, United States
Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome
- Conditions
- Dry Eye Syndrome
- Interventions
- Drug: Placebo corn oil capsule
- First Posted Date
- 2010-04-21
- Last Posted Date
- 2017-12-22
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 27
- Registration Number
- NCT01107964
- Locations
- 🇺🇸
Penn State Hershey Eye Center, Hershey, Pennsylvania, United States
Fenofibrate and Omega-3 Fatty Acid Modulation of Endotoxemia
- Conditions
- Cardiovascular Disease
- Interventions
- First Posted Date
- 2010-01-13
- Last Posted Date
- 2016-02-19
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 100
- Registration Number
- NCT01048502
- Locations
- 🇺🇸
Clinical and Translational Research Center (CTRC); Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Pilot Study of Lovaza (Omega 3 Fatty Acids) to Improve Cardiac Antioxidant/Anti-inflammatory Profile Before Cardiac Surgery
- Conditions
- Left Atrium Dilatation and HypertrophyCardiomyocyte ApoptosisCardiac InflammationMitochondrial Dysfunction in the HeartMitral Valve Regurgitation
- Interventions
- First Posted Date
- 2010-01-12
- Last Posted Date
- 2013-09-10
- Lead Sponsor
- East Carolina University
- Target Recruit Count
- 24
- Registration Number
- NCT01046604
- Locations
- 🇺🇸
Brody School of Medicine, Greenville, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.